TuHURA Biosciences, Inc./NV — Director's Dealing 2021

Apr 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kintara Therapeutics, Inc. (KTRA)
CIK: 0001498382
Period of Report: 2021-04-29

Reporting Person: Brown Dennis M (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-29	Common Stock	J	6	—	Acquired	6068	Direct
2021-04-29	Common Stock	C	750	—	Acquired	6818	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-29	Series B Convertible Preferred Stock	$	C	3000	Disposed		Common Stock (750)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	53750	Indirect

Footnotes

F1: The shares were issued as dividends to April 29, 2021 on the reporting person's shares of Series B Preferred Stock.

F2: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock.

F3: Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00.

F4: Held by Valent Technologies LLC, of which the reporting person is the sole member and owner and holds sole voting and dispositive power over its shares.